Skip to main content

Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States

Advances in Therapy volume 33, pages 1316–1330 (2016)Cite this article

Abstract

Introduction

New treatments for chronic hepatitis C virus (HCV) are highly effective in patients coinfected with human immunodeficiency virus (HIV). This study estimated the cost-effectiveness of treatments for genotype 1 (GT1) HCV in HIV-coinfected patients.

Methods

A Markov model based on HCV natural history was used. The base-case analysis included both treatment-naïve and -experienced patients. Alternatives were ombitasvir/paritaprevir/ritonavir, dasabuvir with or without ribavirin (3D ± R) for 12 or 24 weeks, sofosbuvir plus peginterferon and R (SOF + PR) for 12 weeks, SOF + R for 24 weeks, and no treatment (NT). A subgroup analysis restricted to treatment-naïve, non-cirrhotic patients compared 3D ± R for 12 weeks to SOF plus ledipasvir (LDV) for 12 weeks and NT. Transition probabilities, utilities, and costs were obtained from the published literature. Outcomes were measured over a lifetime horizon and included rates of compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma and liver-related death, total costs, life-years, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER).

Results

In the base-case, SOF + R was dominated by both SOF + PR and 3D ± R. Compared to SOF + PR, 3D ± R had an ICER of $45,581. The lifetime rates of liver morbidity and mortality were lower among those treated with 3D ± R compared to SOF + PR, SOF + R, or NT. In the subgroup analysis, 3D ± R was cost-effective compared to NT at a threshold of $50,000 per QALY (ICER $27,496). SOF/LDV had an ICER of $104,489 per QALY gained compared to 3D ± R.

Conclusion

In the GT1 HCV population coinfected with HIV, 3D ± R was cost-effective compared to NT, SOF + R, and SOF + PR. In the treatment-naïve sub-population, 3D ± R was cost-effective compared to NT and SOF/LDV.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164–70.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14 (United States).

    Article  PubMed  Google Scholar 

  3. CDC. Disease burden from viral hepatitis A, B, and C in the United States. http://www.cdc.gov/hepatitis/PDFs/disease_burden.pdf. Accessed 15 June 2016.

  4. Clausen LN, Lundbo LF, Benfield T. Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol. 2014;20:12132–43.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas—2012. HIV Surveillance Supplemental Report 2014;19(3). http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed 30 May 2015.

  6. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353–61 (United States).

    Article  PubMed  Google Scholar 

  7. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597–605.

    CAS  Article  PubMed  Google Scholar 

  8. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86–96 (United States).

    PubMed  Google Scholar 

  9. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087–97.

    CAS  Article  PubMed  Google Scholar 

  10. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223–31 (United States).

    CAS  Article  PubMed  Google Scholar 

  11. Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002;162(22):2545–56.

    Article  PubMed  Google Scholar 

  12. Hornberger J, Torriani FJ, Dieterich DT, et al. Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol. 2006;36(4):283–91 (Netherlands).

    CAS  Article  PubMed  Google Scholar 

  13. Campos NG, Salomon JA, Servoss JC, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med. 2007;120(3):272–9 (United States).

    Article  PubMed  PubMed Central  Google Scholar 

  14. AASLD-IDSA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. Accessed 30 May 2015.

  15. Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A, et al. Sofosbuvir and Peginterferon alfa-2a/Ribavirin Treatment of naïve Genotype 1–4 HCV infected patients that are coinfected with HIV. San Francisco: ID Week; 2013.

    Google Scholar 

  16. Rodriguez-Torres M, Gaggar A, Shen G, et al. Sofosbuvir for chronic hepatitis C virus infection genotype 1–4 in patients coinfected with HIV. J Acquir Immune Defic Syndr. 2015;68:543–9.

    CAS  Article  PubMed  Google Scholar 

  17. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385:1098–106.

    CAS  Article  PubMed  Google Scholar 

  18. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232–9.

    CAS  Article  PubMed  Google Scholar 

  19. Liu S, Cipriano LE, Holodniy M, et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156(4):279–90 (United States).

    Article  PubMed  PubMed Central  Google Scholar 

  20. Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014;40:657–75.

    CAS  Article  PubMed  Google Scholar 

  21. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–9 (United States).

    CAS  Article  PubMed  Google Scholar 

  22. Thein HH, Yi Q, Dore GJ, et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979–91 (England).

    Article  PubMed  Google Scholar 

  23. Wright M, Forton D, Main J, Goldin R, Torok E, Tedder R, Grant P, Thursz M, Naoumov N, Millson C, Mills PR, Bassendine M, Thomas HC, UK Mild HCV Trial investigators. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat. 2005;12(1):58–6.

    CAS  Article  PubMed  Google Scholar 

  24. Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011;15(17):1–210. doi:10.3310/hta15170.

    Article  Google Scholar 

  25. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162:407–19.

    Article  PubMed  Google Scholar 

  26. Rein DB, Wittenborn JS, Smith BD, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis. 2015;61:157–68.

    Article  PubMed  Google Scholar 

  27. Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41:544–63.

    CAS  Article  PubMed  Google Scholar 

  28. San Miguel R, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut. 2015;64:1277–88.

    Article  PubMed  Google Scholar 

  29. Saab S, Parisé H, Virabhak S, Wang A, Marx SE, Sanchez Gonzalez Y, Misurski D, Johnson S. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ. 2016;24:1–11 (Epub ahead of print).

    Google Scholar 

  30. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652–7.

    CAS  Article  PubMed  Google Scholar 

  31. Siebert U, Sroczynski G, Aidelsburger P, et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics. 2009;27:341–54.

    Article  PubMed  Google Scholar 

  32. McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531–46.

    PubMed  Google Scholar 

  33. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518–31.

    CAS  Article  PubMed  Google Scholar 

  34. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–65.

    CAS  Article  PubMed  Google Scholar 

  35. Gao X, Stephens JM, Carter JA, et al. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2012;12:335–43.

    Article  PubMed  Google Scholar 

  36. Olufade T, Devine S, Dutko F, et al. A cost-minimization analysis of ribavirin dose reduction versus erythropoietin based anemia management in treatment-naive genotype 1 chronic hepatitis C patients treated boceprevir plus peginterferon alfa & ribavirin. Hepatology. 2013;58:386A.

    Google Scholar 

  37. Brogan AJ, Talbird SE, Thompson JR, et al. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One. 2014;9:e90295.

    Article  PubMed  PubMed Central  Google Scholar 

  38. RED BOOK Online [database online]. Greenwood Village, CO: Truven Health Analytics Micromedex Solutions; 2014.

  39. Stepanova M, Nader F, Cure S, et al. Patients’ preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014;40:676–85.

    CAS  Article  PubMed  Google Scholar 

  40. Bedossa P, Poynard T, The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24(2):289–93.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

Design, analysis, and financial support of this study were provided by AbbVie. AbbVie is the manufacturer of ombitasvir/paritaprevir/ritonavir, dasabuvir (3D, Viekira Pak™) which is one of the drugs included in the analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. The authors gratefully acknowledge the assistance of Glen Schumock at Second City Outcome Research LLC in drafting and editing the manuscript. AbbVie provided funding to Second City Outcome Research LLC for drafting and editing the manuscript. AbbVie also funded the article processing charges for this publication.

Disclosures

Sammy Saab is employed by the Pfleger Liver Institute at UCLA and is a consultant for AbbVie. He is also a consultant and on the speaker bureau for BMS, Gilead, Merck and Janssen pharmaceuticals. Suchin Virabhak and Scott Johnson are employed by Medicus Economics LLC, which received payment from AbbVie to undertake research. Hélène Parisé is a contractor for Medicus Economics LLC. Alice Wang, Yuri Sanchez Gonzalez, and Timothy Juday are AbbVie employees and may own AbbVie stock. Derek Misurski is a former AbbVie employee and may own AbbVie stock.

Compliance with Ethics Guidelines

This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Pfleger Liver Institute, UCLA, Los Angeles, CA, USA

    Sammy Saab

  2. Medicus Economics LLC, Milton, MA, USA

    Suchin Virabhak, Hélène Parisé & Scott Johnson

  3. Health Economics and Outcomes Research, AbbVie, Inc., Mettawa, IL, USA

    Alice Wang, Derek Misurski, Yuri Sanchez Gonzalez & Timothy Juday

Authors
  1. Sammy Saab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suchin Virabhak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hélène Parisé
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alice Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Derek Misurski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuri Sanchez Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Timothy Juday
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alice Wang.

Additional information

Enhanced content To view enhanced content for this article go to www.medengine.com/Redeem/6AD4F06059D47858.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Saab, S., Virabhak, S., Parisé, H. et al. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. Adv Ther 33, 1316–1330 (2016). https://doi.org/10.1007/s12325-016-0362-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-016-0362-1

Keywords

  • Cost-effectiveness
  • Direct-acting antivirals
  • Hepatitis C virus
  • Human immunodeficiency virus
  • Infectious diseases